Cas:25501-32-0 (1S)-2,3-dihydro-1H-inden-1-ol manufacturer & supplier

Chemical Name:(1S)-2,3-dihydro-1H-inden-1-ol

CAS.NO:25501-32-0

Synonyms:(1S)-2,3-dihydro-1H-inden-1-ol;(S)-2,3-dihydro-1H-inden-1-ol;(1S)-Indan-1-ol;MFCD00064165;(1S)-1-Indanol;1H-Inden-1-ol, 2,3-dihydro-, (1S)-

Molecular Formula:C₉H₁₀O

Molecular Weight:134.175

HS Code:2906299090

Physical and Chemical Properties:

Melting point:69-73ºC

Boiling point:255.1±9.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.609

PSA:20.23000

Exact Mass:134.073166

LogP:1.49

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like (1S)-2,3-dihydro-1H-inden-1-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Inden-1-ol, 2,3-dihydro-, (1S)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1S)-1-Indanol Use and application,(1S)-2,3-dihydro-1H-inden-1-ol technical grade,usp/ep/jp grade.

Related News: What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. (1S)-2,3-dihydro-1H-inden-1-ol manufacturer With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near (1S)-2,3-dihydro-1H-inden-1-ol supplier As you can see, a considerable number of staff is involved in the production phase until an API is finally manufactured. (1S)-2,3-dihydro-1H-inden-1-ol vendor What’s the background? (1S)-2,3-dihydro-1H-inden-1-ol factory What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL.